Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Not Applicable

Completed

• Conditions: Immunosuppression
• Interventions: Drug: Myfortic

• Registration Number: NCT00336895
• Lead Sponsor: University of Pittsburgh

Brief Summary

The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.

Detailed Description

This is a prospective, single center, open-label, safety and tolerability study on the use of Myfortic after liver transplantation. Adult liver transplant patients who are experiencing GI symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia) attributable to CellCept are eligible to enter the study. CellCept will be discontinued and replaced with Myfortic. The duration of the study will be 3 months, and during this time, we will assess the incidence and severity of GI adverse events, the incidence and severity of bone marrow suppression (leukopenia), and the incidence of cytomegalovirus (CMV) infection or disease in patients receiving Myfortic.

Study Timeline

• Study First Submitted: 2006-06-12
• Study First Submitted QC: 2006-06-12
• Study First Posted: 2006-06-14
• Study Start: 2006-11
• Primary Completion: 2008-11
• Study Completion: 2008-11
• Results First Submitted: 2016-05-19
• Status Verified: 2016-11
• Results First Submitted QC: 2016-11-03
• Last Update Submitted: 2016-11-03
• Results First Posted: 2016-11-06
• Last Update Posted: 2016-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• ALL patients will be adult liver transplant recipients, males or females, 18-80 years of age
• Patients currently receiving tacrolimus or cyclosporine with or without corticosteroids as part of their immunosuppressive regimen
• Patients must be receiving CellCept and must have attributable G.I. symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia)
• Patients must be more than 30 days post-transplant to be eligible
• Females of childbearing potential must have a negative serum pregnancy test prior to the inclusion period

Read More

Exclusion Criteria

• Multi-organ transplant patients
• HIV positive patients.
• Living-related liver transplant recipients
• Pregnant patients
• Patients with a history of extra-hepatic malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin
• Patients with thrombocytopenia (<50,000/mm3), with an absolute neutrophil count of <1,000/mm3 and/or leukocytopenia (<2,000/mm3), and/or hemoglobin <7.0 g/dL prior to enrollment
• Patients with a G.I. clinical problem at the time of enrollment (e.g. CMV infection or disease, C. difficile colitis, active peptic ulcer disease, gastroenteritis, inflammatory bowel disease)
• Presence of clinically significant infection requiring continued therapy or uncontrolled diabetes mellitus
• Evidence of drug and/or alcohol abuse
• Decisionally impaired subjects who are not medically or mentally capable of providing consent themselves

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Liver Transplant Subjects	Myfortic	All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.

Primary Outcome Measures

Name	Time	Method
Gastrointestinal Side Effects and Quality of Life (Total Score of GSRS)	screening, 2, 6 and 12 weeks	The gastrointestinal Symptom Rating Scale (GSRS) is a validated scale, the items range from 1= No discomfort at all to 7= Very severe discomfort.; The scale ranges from a minimal value of 15 ( No discomfort at all) to a maximum of 105 ( Very severe discomfort); The GSRS contains 15 items, each rated on a seven- point likert scale from no discomfort to very severe discomfort. Based on a factor analysis, the 15 GSRS items breakdown into the following five scales: abdominal ( Abdominal pain, hunger pains and nausea): reflux syndrome (heartburn and acid regurgitation), diarrhea syndrome (diarrhea, loose stools and urgent need for defecation), indigestion syndrome ( borborygmus, abdominal distention, eructation and increased flatus) and constipation syndrome (constipation, hard stools and feeling of incomplete evacuation)
Number of Participants With Cytomegalovirus Infection or Disease	12 weeks
Gastrointestinal Side Effects and Quality of Life (-Subscales of GSRS)	12 weeks	The GSRS contains 15 items, each rated on a seven- point likert scale from no discomfort to very severe discomfort. Based on a factor analysis, the 15 GSRS items breakdown into the following five scales: abdominal ( Abdominal pain, hunger pains and nausea): reflux syndrome (heartburn and acid regurgitation), diarrhea syndrome (diarrhea, loose stools and urgent need for defecation), indigestion syndrome ( borborygmus, abdominal distention, eructation and increased flatus) and constipation syndrome (constipation, hard stools and feeling of incomplete evacuation) The range of the scale for abdominal pain was 3 to 21, reflux 2 to 14, diarrhea 3 to 21, indigestion 4 to 28 and constipation 3 to 21.; Higher values represent more severe discomfort.

Trial Locations

Locations (1)

University of Pittsburgh Medical Center; 🇺🇸 Pittsburgh, Pennsylvania, United States